EpilepsyNCT07883980
Antiseizure Medications and CBC in Children With Epilepsy
An observational study of Epilepsy, run by Assiut University.
Trial summary
This prospective study aims to assess changes in complete blood count parameters among Egyptian children with epilepsy receiving antiseizure medications. Read more about this study
- Who is it for?
- Ages 1 year to 18 years
- Conditions the study is for
- Epilepsy
- How many people
- 80 participants
- Where
- No sites listed yet
- Study dates
- 20 Oct 2026to 1 Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Egyptian children aged 1 to 18 years newly diagnosed with epilepsy who have not previously received antiseizure medications, followed at Assiut University Children's Hospital.
Who may be able to join
- Children aged 1 to 18 years
- Diagnosed with epilepsy
- Newly diagnosed and not previously received antiseizure medications
- Written informed consent from parent or legal guardian
Who cannot join
- Known hematological disorders
- Known bone marrow disorders
- Known malignancy
- Chronic liver disease
- Chronic kidney disease
- Active infection at the time of assessment
Show all 9Show fewer
- Recent blood transfusion
- Current use of medications known to affect hematopoiesis
- Known immunodeficiency or systemic inflammatory disease
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effect of Antiseizure Medications on Complete Blood Count Parameters Among Egyptian Children With Epilepsy
This prospective study aims to assess changes in complete blood count parameters among Egyptian children with epilepsy receiving antiseizure medications.
Read the detailed description
Antiseizure medications are the mainstay of treatment for children with epilepsy. Some of these medications may affect hematological parameters including hemoglobin, white blood cell count, and platelet count.
This observational study will evaluate complete blood count parameters in newly diagnosed children with epilepsy before starting antiseizure medication and at follow-up time points after treatment initiation.
- Conditions
- Epilepsy
- Keywords
- Antiseizure medications, Complete blood count, Children, Epilepsy, Assiut
- Medical subject headings
- Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Children with Epilepsy on Antiseizure Medications | Newly diagnosed children with epilepsy who will receive antiseizure medications and undergo serial complete blood count assessments. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in platelet count
Mean change in platelet count from baseline after initiation of antiseizure medication.
Measured: At 3 months
Secondary outcomes (4)
Change in hemoglobin level
Mean change in hemoglobin level from baseline after initiation of antiseizure medication.
Measured: At 3 months
Change in white blood cell count
Mean change in white blood cell count from baseline after initiation of antiseizure medication.
Measured: At 3 months
Change in absolute neutrophil count
Mean change in absolute neutrophil count from baseline after initiation of antiseizure medication.
Measured: At 3 months
Mean Platelet Count at 6 Months
Mean platelet count at 6 months after initiation of antiseizure medication..
Measured: At 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2026
- Study start20 Oct 2026 (estimated)
- Primary completion20 Oct 2027 (estimated)
- Study completion1 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kholoud Ahmed Ali, Assiut University
- Investigators
- Mostafa m Embaby, prof, Study chair, Pediatrics Department, Assiut University Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07883980
- Sponsor's protocol ID
- ASM-CBC-Assiut-2026
- Status last verified
- Oct 2026
- First submitted
- 14 Oct 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Antiseizure Medications on Complete Blood Count Parameters Among Egyptian Children With Epilepsy
- ClinicalTrials.gov ID
- NCT07883980
- Acronym / sponsor ID
- ASM-CBC-Assiut-2026
- Conditions
- Epilepsy
- Keywords
- Antiseizure medications, Complete blood count, Children, Epilepsy, Assiut
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 20 Oct 2026 (estimated)
- Primary completion
- 20 Oct 2027 (estimated)
- Study completion
- 1 Mar 2028 (estimated)
- First posted
- 20 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective study aims to assess changes in complete blood count parameters among Egyptian children with epilepsy receiving antiseizure medications.
Detailed description
Antiseizure medications are the mainstay of treatment for children with epilepsy. Some of these medications may affect hematological parameters including hemoglobin, white blood cell count, and platelet count.
This observational study will evaluate complete blood count parameters in newly diagnosed children with epilepsy before starting antiseizure medication and at follow-up time points after treatment initiation.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Children with Epilepsy on Antiseizure Medications | – | –Newly diagnosed children with epilepsy who will receive antiseizure medications and undergo serial complete blood count assessments. |
Who may qualify
- Ages
- 1 year to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Egyptian children aged 1 to 18 years newly diagnosed with epilepsy who have not previously received antiseizure medications, followed at Assiut University Children's Hospital.
Key inclusion criteria (4 listed)
- Children aged 1 to 18 years
- Diagnosed with epilepsy
- Newly diagnosed and not previously received antiseizure medications
- Written informed consent from parent or legal guardian
Key exclusion criteria (9 listed)
- Known hematological disorders
- Known bone marrow disorders
- Known malignancy
- Chronic liver disease
- Chronic kidney disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change in platelet count
Time frame: At 3 months
Mean change in platelet count from baseline after initiation of antiseizure medication.
4 secondary outcomes
Change in hemoglobin level
Time frame: At 3 months
Change in white blood cell count
Time frame: At 3 months
Change in absolute neutrophil count
Time frame: At 3 months
Mean Platelet Count at 6 Months
Time frame: At 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Epilepsy
Not yet recruiting
Clinical Trial of SEEG for Drug-resistant Epilepsy
Drug-Resistant Epilepsy
RecruitingPhase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Seizures, Lennox Gastaut Syndrome
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Focal Seizure, Epilepsy
Active, not recruitingObservational study
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)
Traumatic Brain Injury, Post-traumatic Epilepsy
RecruitingPhase 3
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Focal Seizure, Epilepsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mostafa m Embaby, prof study chair
Pediatrics Department, Assiut University Hospitals
Questions about this trial
What is this clinical trial studying?
An observational study of Epilepsy, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kholoud A Ali (01128012630, khlaud.17289902@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in platelet count (time frame: At 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2026.